EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Nextage Therapeutics's enterprise value is ₪22.55 Mil.
Nextage Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was ₪0.88 Mil. Therefore, Nextage Therapeutics's EV-to-Revenue for today is 25.74.
The historical rank and industry rank for Nextage Therapeutics's EV-to-Revenue or its related term are showing as below:
XTAE:NXTG'
s EV-to-Revenue Range Over the Past 10 Years
Min: 11.88 Med: 125.27 Max: 750.56
Current: 25.74
During the past 8 years, the highest EV-to-Revenue of Nextage Therapeutics was 750.56. The lowest was 11.88. And the median was 125.27.
XTAE:NXTG's EV-to-Revenue is ranked worse than 93.57% of 1027
companies
in the Drug Manufacturers industry
Industry Median: 2.4
vs XTAE:NXTG: 25.74
Nextage Therapeutics EV-to-Revenue Historical Data
The historical data trend for Nextage Therapeutics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Nextage Therapeutics's EV-to-Revenue
For the Drug Manufacturers - Specialty & Generic subindustry, Nextage Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nextage Therapeutics's EV-to-Revenue Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Nextage Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Nextage Therapeutics's EV-to-Revenue falls into.
Nextage Therapeutics's current Enterprise Value is ₪22.55 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Nextage Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was ₪0.88 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nextage Therapeutics's share price for today is ₪0.707.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was ₪0.03.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nextage Therapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Nextage Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Nextage Therapeutics (XTAE:NXTG) Business Description
Nextage Therapeutics Ltd is a holding company. The company, through its subsidiaries, is engaged in the development of biological marker, a molecule/gene, which when present in the body at abnormal levels indicates development of a disease. It is focused on the development and commercialization of cancer diagnostic products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XTAE:NXTG has been successfully added to your 